

**I782 CKD**  
**Tweetorial Chat #1 References**

**Tweet 4:**

Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. *Hypertension*. 2005;46:1227-35.  
Britannica.com. Aldosterone. <https://www.britannica.com/science/aldosterone>.

**Tweet 5:**

Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. *Kidney Int*. 2011;79:1051-60.

Capelli I, et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. *J Nephrol*. 2020;33:37-48.

**Tweet 6:**

Agarwal R, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. *Eur Heart J*. 2021;42:152-61.

**Tweet 9:**

Yang J, Young MJ. Mineralocorticoid receptor antagonists – pharmacodynamics and pharmacokinetic differences. *Curr Opin Pharmacol*. 2016;27:78-85.

Agarwal R, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. *Eur Heart J*. 2021;42:152-61.

Dhaybi OA, Bakris GL. Non-steroidal mineralocorticoid antagonists: prospects for renoprotection in diabetic kidney disease. *Diabetes Obes Metab*. 2020;22(Suppl 1):69-76.

**Tweet 10:**

Wada T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. *Clin Exp Nephrol*. 2021;25:120-30.

**Tweet 11:**

Rakugi H, et al. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. *Hypertension Res*. 2019;42:1932-41.

Ito S, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. *Clin J Am Soc Nephrol*. 2020;15:1715-27.

**Tweet 12:**

Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383:2219-29.

## **Glossary**

AEs, adverse effects/events

BP, blood pressure

CCBs, calcium channel blockers

CKD, chronic kidney disease

FDA, Food & Drug Administration

GR, glucocorticoid receptor

MR, mineralocorticoid receptor

RAS, renal artery stenosis

T2D, type 2 diabetes